Verastem Oncology Reports First Quarter 2022 Financial Resul

Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung CancerCompany Secured up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Thr...

Related Keywords

United States , American , Ajay Munshi , Nate Liabraaten , Secura Bio , Elisa Buffington , Brian Stuglik , Chugai Pharmaceutical Co Ltd , Amgen , Drug Administration , Company Annual Report On Form , Exchange Commission , American Association For Cancer Research , Corporate Development , Secura Bio Inc , Group Limited , Corporate Communications , Verastem Oncology Press , Raf And Mek Program , Oxford Finance , Enrollment Completed , Selection Phases , Low Grade Serous Ovarian Cancer , Non Dilutive Funding , Expected Cash Runway Through , Support Continued Development , Potential Commercial Launches , Verastem Oncology , Chief Executive Officer , Grade Serous Ovarian Cancer , American Association , Cancer Research , Non Small Cell Lung Cancer , National Medical Products Administration , Breakthrough Therapy , Annual Report , Oncology Press , Recurrent Low Grade Serous Ovarian , Accessed May , Consolidated Statements ,